Telik Inc.
3165 Porter Drive
Palo Alto,
CA 94304
United States - Map
Phone: 650-845-7700
Fax: 650-845-7800
Web Site: http://www.telik.com
| Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer. The companys advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy; and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Its preclinical drug product candidates for the treatment of cancer comprise TLK60404, a small molecule compound inhibiting Aurora kinase and VEGFR kinase; TLK60357, a small molecule inhibitor of cell division; TLK60596, a small-molecule dual inhibitor of VEGFR1 and VEGFR2 kinase; and TLK58747, a metabolically activated cytotoxic small molecule. Telik's product candidates are discovered using its proprietary drug discovery technology, TRAP that enables the rapid and efficient discovery of small molecule drug candidates. The company was founded in 1988 and is based in Palo Alto, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Michael M. Wick M.D., Ph.D., 64
Chairman, Chief Exec. Officer and Pres |
$
514.00K |
$
120.00K | Ms. Cynthia M. Butitta , 55
Chief Operating Officer, Chief Financial Officer and Principal Accounting Officer |
$
379.00K |
$
116.00K | Mr. William P. Kaplan Esq., 56
VP, Sec. and Gen. Counsel |
N/A
| N/A | Mr. Marc L. Steuer , 63
Sr. VP of Bus. Devel. |
N/A
| N/A | Dr. Gail L. Brown M.D., 59
Chief Medical Officer and Sr. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.42% Nasdaq 
Profile
